Abstract
To evaluate the ability of orally administered liquid levodopa/carbidopa (LD/CD) to stabilize plasma levodopa levels and reduce motor reponse fluctuations in Parkinson's disease, five patients received LD/CD hourly, as standard tablets or as an aqueous solution on two separate days in a double‐blind, placebo‐controlled, cross‐over design. Except for a slightly earlier peak plasma levodopa level, no significant advantage of the liquid formulation over tablet therapy was found. However, liquid LD/CD could be helpful in quickly resolving “off” states and by facilitating small dose adjustments that are not possible with tablets.
Original language | English (US) |
---|---|
Pages (from-to) | 463-465 |
Number of pages | 3 |
Journal | Movement Disorders |
Volume | 9 |
Issue number | 4 |
DOIs | |
State | Published - 1994 |
Keywords
- Clinical trial
- Motor fluctuations
- Parkinson's disease
ASJC Scopus subject areas
- Clinical Neurology
- Neurology